Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAAShell Companies
+$0.00 today
- Market cap
- $264.62M
- Beta
- 0.00
- P/E (TTM)
- 36.7
- EPS (TTM)
- $0.29
Volume 0.00M
Average 0.11M
DMAA Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Drugs Made In America Acquisition Corp. Ordinary SharesNASDAQ: DMAA
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) dips below year-ago levels
Q1 FY2026 weighted avg shares (diluted) of 23M shares fell 9.8% year over year, behind the +96.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 9.5% from the prior quarter.
What to watch
Whether quarterly growth recovers from -9.8% toward the trailing-twelve-month pace of +96.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 21.01M USD
- Year-over-year change
- +145.1%
- 1-year CAGR
- +145.1%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.01M | +145.1% |
| FY2024 | 2024-12-31 | 8.57M | — |
Weighted Avg Shares (Diluted) vs competitors
How DMAA compares with its peers on the latest reported figures
- DMAA's LTM Mar 2026 weighted avg shares (diluted) of 25.13M shares is the 5th highest of the 10 companies compared; the peer median is 24.67M shares.
- Its year-over-year change of +96.3% is the 2nd highest of 5, against a peer median of +11.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 30.66M | — | — | |
| LTM Mar 2026 | 30.55M | +13.3% | — | |
| LTM Mar 2026 | 27.4M | +9.0% | +8.5% | |
TACHTitan Acquisition Corp. | LTM Mar 2026 | 26.75M | +436615.5% | — |
| LTM Mar 2026 | 25.13M | +96.3% | — | |
| LTM Mar 2026 | 24.67M | — | — | |
| LTM Mar 2026 | 23M | -23.4% | — | |
OYSEOyster Enterprises II Acquisition Corp | LTM Mar 2026 | 21.68M | — | — |
| LTM Mar 2026 | 20.49M | — | — | |
TACOUBerto Acquisition Corp. Unit | LTM Mar 2026 | 16.88M | — | — |
| Peer median (excluding DMAA) | 24.67M | +11.1% | +8.5% | |
Competitors are the stored peer set for DMAA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 0 | 0 |
| Gross Margin | — | — |
| Research & Development | 0 | 0 |
| Selling, General & Admin | 480 | 2.82M |
| Operating Expenses | 480 | 2.82M |
| Depreciation & Amortization | 480 | 0 |
| EBITDA | (279.85K) | (2.82M) |
| EBITDA Margin | — | — |
| Operating Income | (479) | (2.82M) |
| Operating Margin | — | — |
| Interest Income | 0 | 8.76M |
| Interest Expense | 0 | 0 |
| Other Income / Expenses | 0 | 8.76M |
| Income Before Tax | (479) | 5.94M |
| Pre-Tax Margin | — | — |
| Income Tax Expense | 0 | 0 |
| Net Income | (479) | 5.94M |
| Net Margin | — | — |
| EPS (Basic) | (0.06) | 0.19 |
| EPS (Diluted) | (0.06) | 0.19 |
| Weighted Avg Shares | 8.57M | 21.01M |
| Weighted Avg Shares (Diluted) | 8.57M | 21.01M |
Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAA
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.